Introduction: NSCLC with de novo anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements and EGFR or KRAS mutations co-occur very rarely. Outcomes with tyrosine kinase inhibitors (TKIs) in these patients are poorly understood.
Introduction
In the Western population EGFR mutations and anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements are found in 10% to 15% and 3% to 7% of lung adenocarcinomas, respectively. 1, 2 In patients with EGFR mutations or ALK rearrangements, specific EGFR and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) improve response rates (RRs) and prolong progression-free survival (PFS) without improving overall survival (OS) compared with standard cytotoxic chemotherapy. [3] [4] [5] [6] [7] KRAS mutations are observed in approximately 20% to 30% of lung adenocarcinomas and are associated with a history of tobacco use and poor prognosis. [8] [9] [10] [11] [12] To date, no mutation-specific therapy for this group of patients has been established.
De novo ALK rearrangements were thought to be mutually exclusive with EGFR or KRAS mutations. 13, 14 However, co-alterations do rarely occur and the incidences of concomitant KRAS mutations with EGFR mutations or ALK rearrangement have previously been reported to be 1.6% and 2.5%, respectively. 15 With the increasing use of next-generation sequencing (NGS)-based mutational profiling, the detection of coalterations is expected to increase in the future, also revealing mutations with a very low frequency. Given the rarity of these co-alterations and the relatively new TKI treatment options, there is limited knowledge about their prognostic and predictive value.
KRAS mutation has been identified as a mechanism of secondary resistance to ALK TKIs such as crizotinib 16, 17 ; thus, ALK and KRAS co-alteration may be associated with primary resistance to ALK TKI treatment. However, the data on clinical outcomes are derived from small series and case reports and only a few patients ever received ALK TKI treatment. 15, 18, 19 Thus, more knowledge to support treatment decisions in this population is needed.
Recent case reports of patients with concomitant alterations of ALK and EGFR [20] [21] [22] [23] have shown controversial results. The interaction (synergism versus dominance) in the setting of two oncogenic driver alterations such as ALK and EGFR and response to TKI treatment is poorly understood. A series of 13 patients with EGFR-and ALK-co-mutated NSCLC suggests that mutant EGFR and ALK fusion proteins are coexpressed and colocalized in the same clone of tumor cells but phosphorylation of proteins differed, constituting different activation status and possibly dominance of one oncogenic alteration over the other. 24 The aim of our study was to analyze the outcome of patients with ALK-positive NSCLC carrying an additional EGFR or KRAS co-mutation and to study responses to TKI treatment in this rare patient population.
Methods
Eligible patients at six oncology centers in Switzerland had advanced NSCLC with a de novo ALK/ KRAS or ALK/EGFR co-alteration; they could have had any previous systemic anticancer treatment or been treatment nave. Patients whose NSCLC was diagnosed between March 2011 and June 2016 were included in this retrospective analysis. Information about the respective co-alteration was available upfront before TKI treatment. The primary end point was PFS while receiving TKI treatment. Secondary end points were RR and disease control rate (DCR) during treatment with a TKI or chemotherapy and OS. Patients must have received adequate follow-up, including documented radiological evaluation of tumor manifestations (i.e., computed tomography scan every 2 or 3 months). Clinical and pathological data of each patient were collected by the locally treating Good Clinical Practice-certified oncologist. Anonymized data were documented and analyzed at the coordinating center in St. Gallen.
Clinical stage was assessed locally according to the TNM classification, version 7. 25 Patient and tumor characteristics, therapy information, and treatment outcomes were collected. Responses were defined according to the Response Evaluation Criteria in the Solid Tumors guidelines, version 1.1. Tumor assessments were performed locally. ALK rearrangement was analyzed by fluorescence in situ hybridization (FISH) with probes from either ZytoVision (Bremerhaven, Germany) or Abbott Molecular (Des Plaines, IL). The cutoff for ALK positivity was 15% split signals. EGFR and KRAS mutations were identified by Sanger sequencing or NGS. In the two cases in which NGS was performed, ion torrent sequencing (Life Technologies, Carlsbad, CA) with the AmpliSeq Cancer Hotspot Panel, version 2 (Thermo Fisher Scientific, Waltham, MA) were utilized. PFS was defined as time from start of TKI treatment to progression, OS was defined as time from beginning of first-line treatment to death. DCR was defined as CR, PR, or stable disease. Patients not experiencing an event were censored at the time of data cutoff (June 30, 2016) or at the last contact if lost to follow-up. Time-to-event end points were analyzed by the Kaplan-Meier method.
Approval from the ethics committee of St. Gallen (Lead Ethics), as well as from the ethics committees of Ticino, Zürich, and Central Switzerland, was obtained before starting data collection.
Results
A total of 14 patients with de novo ALK/KRAS or ALK/ EGFR co-alterations were identified; 57% were females, and the tumor stages were IIIB (7%), IVA (21%) and IVB (71%). All NSCLCs were adenocarcinomas. Patients with ALK/EGFR co-alterations were less likely to be current or former smokers than were patients with ALK/KRAS coalterations (40% versus 88%) (see Table 1 for detailed patient characteristics). ALK immunohistochemistry (IHC) testing was performed in four patients, as initial Overall, 13 patients received at least one targeted therapy: 11 patients received an ALK TKI (crizotinib, alectinib, ceritinib, or lorlatinib) and four patients received an EGFR TKI (erlotinib, afatinib, or osimertinib). Figure 1 shows the sequence and duration of systemic treatment, including TKI, chemotherapy, and immunotherapy in individual patients, in a swimmers plot. The median OS of all patients was 47.1 months (range 11-78 months or longer, with six patients still alive at the date of last contact). The median follow-up was 42.6 months; one patient was lost to follow-up. Only three patients in our cohort (two with ALK/KRAS co-mutation and one with ALK/EGFR co-mutation) have received treatment with checkpoint inhibitors (all nivolumab), and all patients were primary refractory.
Patients with ALK/KRAS Co-alteration
Nine patients with ALK/KRAS co-alteration were identified. All KRAS mutations occurred in codon 12. Their median age was 58 years (range 35-83), and 88% of the patients were former or active smokers (Table 1) .
Crizotinib was given as first-line therapy in three patients, as second-line therapy in four, and as fifth-line treatment in one, respectively; none of the patients with ALK/KRAS co-alteration received more than one line of ALK TKI treatment. Six of seven patients evaluable for response (86%) were primary refractory to ALK TKI treatment (all receiving crizotinib). One patient stopped taking crizotinib before the first radiographic assessment on account of toxicity. The DCR was only 12.5%. However, one patient has had ongoing disease stabilization for 26 months, but without documented tumor shrinkage. One patient with ALK/KRAS coalteration has not been treated with an ALK TKI to date, as he received first-line chemotherapy with carboplatin and pemetrexed and is currently still receiving pemetrexed maintenance therapy. When the data on the three patients with additional ALK IHC results available were analyzed, neither the two FISH-positive/IHCnegative patients nor the one FISH-positive/IHCpositive patient responded to an ALK TKI. Three of seven patients (43%) responded to platinum-based chemotherapy (six patients in the first-line setting and one in the second-line setting), with a median PFS of 4.0 months (range 1.2-41.5 months with ongoing treatment). Only two patients were also treated with an immune checkpoint inhibitor (see Fig. 1 ). The median OS of all patients with ALK/KRAS co-alteration was 47.1 months (range 11-77.5 months, with three patients still alive at the date of last contact).
Patients with ALK/EGFR Co-alteration
Five patients with ALK/EGFR co-alteration were identified. Their median age was 60 years (range 30-70 years), and 40% were former or active smokers (see Table 1 ). All received one or more EGFR or ALK TKIs in various treatment lines.
Response to ALK TKIs. One of the three patients with an ALK/EGFR co-alteration responded to ALK TKI monotherapy. This patient had a PR to first-line alectinib (time on treatment 6 months) followed by another PR to fifth-line lorlatinib (time on treatment 3 months) but was refractory to fourth-line ceritinib. This patient was ALK IHC-positive and ALK FISH-positive. One patient had a PR to third-line crizotinib/erlotinib combination therapy, and one patient was primary refractory to second-line therapy with crizotinib. Two patients never received ALK TKI treatment. The median PFS while receiving a first ALK TKI was 5.7 months (1.3, 5.7, and 7.3 months).
Response to EGFR TKIs. Three out of the four patients with ALK/EGFR co-alteration (75%) treated with an EGFR TKI achieved one or more responses in different lines of therapy: PR was achieved three times with afatinib and once with osimertinib, and CR was achieved once with osimertinib (see Fig. 2 for an example of a patient with ALK/EGFR co-alteration responding to osimertinib). One patient was primary refractory to second-line erlotinib and to third-line afatinib. EGFR TKI treatment was given as first-line therapy in one patient, as second-line therapy in two, as third-line therapy in three (one in combination with crizotinib), and as fourthline therapy in two. One patient received three lines of EGFR TKI treatment, two patients received two lines, and one patient received one line. One patient with an exon 20 mutation was never treated with an EGFR TKI. The median PFS while receiving a first EGFR TKI was 5.8 months (range 3.0-6.9 months). One of the four patients responded to platinum-based chemotherapy, with a median PFS of 3.3 months (range 0.3-8.4 months).
The median OS of all patients with ALK/EGFR co-alteration was 32.9 months (range 21-33 months, with three patients still alive at the date of last contact).
Discussion
We have herein reported the clinical outcomes during TKI treatment of patients with adenocarcinoma of the lung harboring de novo ALK/KRAS or ALK/EGFR coalterations. We demonstrated that de novo concurrent ALK/KRAS alterations were associated with resistance to ALK TKI treatment in six of seven patients. We also found that in patients with ALK/EGFR co-alterations EGFR TKIs may be more active than ALK TKIs, with three out of four and one out of three patients responding to the corresponding TKI, respectively. Table 2 summarizes published data on ALK-coaltered patients, including patients with ALK/KRAS and ALK/EGFR co-mutations, which are mentioned in the following paragraphs. Previous studies of patients with ALK/KRAS co-alterations have mainly focused on the frequency of this co-alteration, whereas data on response to TKI treatment are scarce. 
April 2017
De Novo EGFR or KRAS Co-Mutations with TKIs
Our findings support previous observations in smaller series, which also suggested inferior outcomes of this rare subset of patients with ALK TKI therapy. 15, 19 In the series of Ulivi et al., of seven patients with ALK/KRAS co-alteration (median age 76 years, all with a history of tobacco consumption) only three patients actually received treatment with an ALK TKI. There was no response to therapy, and only one patient achieved stable disease as the best response. Median OS in these co-altered patients was worse than in patients with only an ALK translocation, suggesting poorer outcome of co-altered patients. 15 In another series of 14 patients, only one patient received crizotinib, with rapid disease progression after an initial response. 19 Furthermore, DCR may depend on the type of KRAS mutation (codon 12 versus codon 13), with codon 13 mutations associated with worse outcome. 28 In our series, all nine ALK/KRAS-co-altered patients had mutations in codon 12, and despite the lack of response to ALK TKI treatment, their median OS was 47.1 months. We observed that two of these patients had very longlasting remissions while receiving chemotherapy, contributing to the favorable survival outcomes. None of the three patients (two with ALK/KRAS co-alteration and one with ALK/EGFR co-alteration) treated with nivolumab responded. Further studies are needed to demonstrate a potentially limited benefit of checkpoint inhibitors in these patients.
To the best of our knowledge, the current series is the largest analysis to date with evaluation of the response to ALK TKI treatment in patients with an ALK/KRAS coalteration. One patient achieved ongoing disease stabilization for 26 months in our series. However, there was no tumor shrinkage in this patient, indicating that this was likely due to a more indolent disease course rather than an antitumor activity of the ALK TKI. Our results therefore support previous reports that platinum-based chemotherapy should be the first-line treatment for patients with ALK/KRAS co-alterations.
With respect to ALK/EGFR co-alterations, we found that EGFR TKIs were more active than ALK TKIs, with one out of three patients responding to an ALK TKI and three out of four patients responding to an EGFR TKI. Previous case reports and small series on tumor response to EGFR and ALK TKIs in patients with ALK/EGFR co-alteration reported conflicting results. 15, 19, 24, 26, 27 Intratumor heterogeneity of ALK rearrangement as well as different phosphorylation levels of the oncogenic drivers may partly explain the varying RRs to ALK and EGFR TKIs seen in ALK/EGFR-co-altered patients. 24, 29 In the series from Ulivi et al., clinical benefit defined as DCR from EGFR TKI was reported in 67% of the six co-altered patients, which is a numerically lower rate than the 81.7% in patients with an EGFR mutation only. Crizotinib was given to only one patient, who was then primary refractory. 15 In contrast, another series with 14 co-altered patients showed DCR with crizotinib in eight patients, but tumor response to an EGFR TKI was not seen in three patients However, the EGFR mutation was detected by polymerase chain reaction in only four of the 14 patients, whereas in the remaining 10 patients methods with a higher sensitivity, such as real-time polymerase chain reaction, targeted NGS, or mutant-enriched NGS were applied, suggesting lower EGFR mutation burden as a potential reason for the lack of benefit of EGFR TKIs in these patients. 27 In our study, of the five patients with EGFR/ALK coalteration, four received one or more lines of EGFR TKI treatment (a maximum of three lines) and three patients received one or more lines of ALK TKI treatment (a maximum of three lines). Median PFS and RR were slightly better with EGFR TKIs than with ALK TKIs; however, the results remain controversial and preliminary because of the small sample size. Unlike our series, previous studies have not evaluated patients receiving several lines of TKI and none of these series have included patients treated with third-generation EGFR TKIs or multiple second-generation ALK TKIs. Both patients treated with the third-generation EGFR TKI osimertinib showed ongoing tumor response (one with a PR and one with a CR).
This study certainly has a number of limitations that have to be taken into consideration when interpreting our results. Utmost, this is a retrospective study with a relatively small sample size. However, given the rarity of these co-alterations, our analysis is still the largest reporting TKI treatment outcomes in ALK/KRAS-coaltered patients and one of the few reports adding to the limited knowledge on treatment outcomes in EGFR/ ALK-co-altered patients. Furthermore, we cannot exclude false-positive ALK FISH tests. Worse outcomes in response to ALK TKIs in both cohorts (ALK/EGFRand ALK/KRAS-co-altered patients) may be partly related to false-positive ALK FISH results. The accepted standard to establish positive ALK translocation status is the FISH test, which was used as reference method in clinical trials, but recently IHC-based assays analyzing ALK protein expression have also been approved by the U.S. Food and Drug Administration and other regulatory authorities to identify patients with NSCLC eligible for treatment with an ALK TKI. In general, ALK FISH and IHC results show high concordance that differs slightly depending on the assay used for IHC. In a retrospective analysis, only 1.2% of tumors (123 of 10,388) showed discordant results (ALK FISH-positive/IHC-negative or FISH-negative/IHC-positive results) and follow-up information on treatment response was available for 35 cases. 30 In ALK FISH-negative/IHC-positive patients, the RR to crizotinib was 100%, whereas in ALK FISHpositive/IHC-negative patients, the RR was only 46%. In our series, ALK IHC was performed in only four patients, limiting interpretation of results in this respect.
In conclusion, KRAS mutations are associated with resistance to ALK TKI therapy in ALK rearrangementpositive lung adenocarcinoma. Thus, platinum-based chemotherapy should be the first-line treatment of choice for these patients. In patients with ALK/EGFR-coaltered lung adenocarcinoma, treatment outcomes with ALK or EGFR TKIs seem inferior to the results one would expect with either molecular alteration alone. EGFR TKI treatment may be associated with better outcomes in these patients compared with ALK TKI treatment; however, further studies are needed to clarify which patients may still benefit from the respective TKIs.
